{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:43Z","timestamp":1784180263655,"version":"3.55.0"},"reference-count":224,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.arr.2025.102693","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T22:11:10Z","timestamp":1739657470000},"page":"102693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Does drug repurposing bridge the gaps in management of Parkinson\u2019s disease? Unravelling the facts and fallacies"],"prefix":"10.1016","volume":"105","author":[{"given":"Bushra","family":"Bashir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukriti","family":"Vishwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshav Raj","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Dureja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunah","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrashabh V.","family":"Sugandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Popat S.","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Disouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralikrishnan","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bey Hing","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2025.102693_bib1","first-page":"737","article-title":"Prevention of progression in Parkinson\u2019s disease","volume":"31","author":"Aaseth","year":"2018","journal-title":"Biometals Int. J. role Met. ions Biol. Biochem. Med."},{"key":"10.1016\/j.arr.2025.102693_bib2","first-page":"2","article-title":"Advantages and challenges in drug re-profiling","volume":"2","author":"Agrawal","year":"2015","journal-title":"J. Pharm."},{"issue":"80","key":"10.1016\/j.arr.2025.102693_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.aar5683","article-title":"LRRK2 kinase in Parkinson\u2019s disease","volume":"360","author":"Alessi","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.arr.2025.102693_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/biom9030100","article-title":"Omega-3 fatty acids prevent post-traumatic stress disorder-induced memory impairment","volume":"9","author":"Alquraan","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.arr.2025.102693_bib5","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","article-title":"Urate as a predictor of the rate of clinical decline in Parkinson disease","volume":"66","author":"Ascherio","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","article-title":"The ongoing pursuit of neuroprotective therapies in Parkinson disease","volume":"11","author":"Athauda","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib8","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2025.102693_bib9","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2025.102693_bib10","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.arr.2025.102693_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib12","article-title":"Identifying novel candidates for re-purposing as potential therapeutic agents for Alzheimer\u2019s disease","author":"Ballard","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.arr.2025.102693_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12098-008-0226-z","article-title":"Neurological disorders in children and adolescents","volume":"76","author":"Banerjee","year":"2009","journal-title":"Indian J. Pediatr."},{"key":"10.1016\/j.arr.2025.102693_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","article-title":"Parkin and PINK1 functions in oxidative stress and neurodegeneration","volume":"133","author":"Barodia","year":"2017","journal-title":"Brain Res. Bull."},{"issue":"4","key":"10.1016\/j.arr.2025.102693_bib15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arr.2025.102693_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102236","article-title":"Opening avenues for treatment of neurodegenerative disease using post-biotics: Breakthroughs and bottlenecks in clinical translation","author":"Bashir","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.arr.2025.102693_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176234","article-title":"Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson\u2019s disease in rats","volume":"962","author":"Bashir","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib18","unstructured":"Bassil, F., Canron, M.-H., Dutheil, N., Vital, A., Bezard, E., Fernagut, P.O., Meissner, W., 2017. Brain insulin resistance in Parkinson\u2019s disease, in: Movement Disorders. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA."},{"key":"10.1016\/j.arr.2025.102693_bib19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib20","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1016\/j.jmb.2018.08.019","article-title":"Ursodeoxycholic acid improves mitochondrial function and redistributes Drp1 in fibroblasts from patients with either sporadic or familial Alzheimer\u2019s disease","volume":"430","author":"Bell","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.arr.2025.102693_bib21","unstructured":"Birkmayer, W., Riederer, P., 2012. Parkinson\u2019s disease: Biochemistry, clinical pathology, and treatment."},{"key":"10.1016\/j.arr.2025.102693_bib22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neurobiolaging.2017.12.009","article-title":"Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice","volume":"64","author":"Bomba","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2025.102693_bib23","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00702-018-1913-1","article-title":"Tetracycline repurposing in neurodegeneration: focus on Parkinson\u2019s disease","volume":"125","author":"Bortolanza","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2025.102693_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2025.102693_bib25","first-page":"589","article-title":"c-Abl and Parkinson\u2019s disease: mechanisms and therapeutic potential","volume":"7","author":"Brahmachari","year":"2017","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2025.102693_bib26","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson\u2019s disease","volume":"32","author":"Brakedal","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/cells10020375","article-title":"Alpha-synuclein: mechanisms of release and pathology progression in synucleinopathies","volume":"10","author":"Br\u00e1s","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.arr.2025.102693_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001854","article-title":"Glitazone treatment and incidence of Parkinson\u2019s disease among people with diabetes: a retrospective cohort study","volume":"12","author":"Brauer","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.arr.2025.102693_bib29","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/brain\/awaa262","article-title":"Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes","volume":"143","author":"Brauer","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.arr.2025.102693_bib30","first-page":"231","article-title":"Linked clinical trials\u2013the development of new clinical learning studies in Parkinson\u2019s disease using screening of multiple prospective new treatments","volume":"3","author":"Brundin","year":"2013","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2025.102693_bib31","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212553","article-title":"The therapeutic role of minocycline in Parkinson\u2019s disease","volume":"8","author":"Cankaya","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.arr.2025.102693_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12017-017-8447-9","article-title":"Deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation","volume":"19","author":"Carboni","year":"2017","journal-title":"NeuroMolecular Med"},{"key":"10.1016\/j.arr.2025.102693_bib33","first-page":"545","article-title":"Simvastatin as a potential disease-modifying therapy for patients with Parkinson\u2019s disease: rationale for clinical trial, and current progress","volume":"7","author":"Carroll","year":"2017","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2025.102693_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"Rejuvenation\u2019protects neurons in mouse models of Parkinson\u2019s disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.arr.2025.102693_bib35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.neuron.2016.01.034","article-title":"A systems-level analysis of the peripheral nerve intrinsic axonal growth program","volume":"89","author":"Chandran","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2025.102693_bib36","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/aje\/kwp033","article-title":"Plasma urate and Parkinson\u2019s disease in the Atherosclerosis Risk in Communities (ARIC) study","volume":"169","author":"Chen","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.arr.2025.102693_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.arr.2025.102693_bib38","article-title":"Pharmacotherapy for Parkinson\u2019s disease","volume":"27","author":"Chen","year":"2007","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.arr.2025.102693_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","article-title":"Aggregation of \u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations","volume":"104","author":"Choi","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.arr.2025.102693_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.freeradbiomed.2004.12.008","article-title":"Enhanced susceptibility to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity","volume":"38","author":"Choi","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2025.102693_bib41","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ijo.2015.136","article-title":"Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes","volume":"39","author":"Christensen","year":"2015","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.arr.2025.102693_bib42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tox.2011.11.020","article-title":"Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells","volume":"292","author":"Chun","year":"2012","journal-title":"Toxicology"},{"key":"10.1016\/j.arr.2025.102693_bib43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2025.102693_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","article-title":"Is cannabidiol the ideal drug to treat non-motor Parkinson\u2019s disease symptoms?","volume":"269","author":"Crippa","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib45","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","article-title":"Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Cudkowicz","year":"2014","journal-title":"Lancet Neurol."},{"issue":"80","key":"10.1016\/j.arr.2025.102693_bib46","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.arr.2025.102693_bib47","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/mds.22798","article-title":"The role of parkin in familial and sporadic Parkinson\u2019s disease","volume":"25","author":"Dawson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib48","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.arr.2025.102693_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jnutbio.2019.02.012","article-title":"N-acetylcysteine and alpha-lipoic acid improve antioxidant defenses and decrease oxidative stress, inflammation and serum lipid levels in ovariectomized rats via estrogen-independent mechanisms","volume":"67","author":"Delgobo","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.arr.2025.102693_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40263-019-00651-1","article-title":"Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets","volume":"33","author":"deVries","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2025.102693_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.arr.2025.102693_bib53","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.arr.2025.102693_bib54","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198209023071010","article-title":"Amantadine as an antiviral agent in influenza","author":"Douglas","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102693_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","article-title":"Iron chelation in the treatment of neurodegenerative diseases","volume":"38","author":"Dusek","year":"2016","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.arr.2025.102693_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ene.12664","article-title":"Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis","volume":"23","author":"Elia","year":"2016","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4236\/ojd.2017.62004","article-title":"Monoamine oxidase inhibitors\u2014revisiting a therapeutic principle","volume":"6","author":"Entzeroth","year":"2017","journal-title":"Open J. Depress"},{"key":"10.1016\/j.arr.2025.102693_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jamaneurol.2019.3983","article-title":"The narrowing path for nilotinib and other potential disease-modifying therapies for Parkinson disease","volume":"77","author":"Espay","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib59","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease: molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.arr.2025.102693_bib60","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2025.102693_bib61","unstructured":"Fernandes, A.S., Silva, S.D., Carvalho, A.N., Amorim, M., Cunha, C.S., Oliveira, P., Thirstrup, K., Castro, A.C.T. de, Maciel, P., 2014. Chronic treatment with 17-DMAG improves balance and coordination in a new mouse model of Machado-Joseph disease."},{"key":"10.1016\/j.arr.2025.102693_bib62","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","article-title":"Drug repurposing in rare diseases: Myths and reality","volume":"75","author":"Fetro","year":"2020","journal-title":"Therapies"},{"key":"10.1016\/j.arr.2025.102693_bib63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1353-8020(03)00040-3","article-title":"Malignant melanoma and levodopa in Parkinson\u2019s disease: causality or coincidence?","volume":"9","author":"Fiala","year":"2003","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"Fiedorowicz","year":"2004","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.arr.2025.102693_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199040010-00004","article-title":"Isradipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease","volume":"40","author":"Fitton","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2025.102693_bib66","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1038\/s41598-019-44803-1","article-title":"Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats","volume":"9","author":"Fletcher","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2025.102693_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.841","article-title":"Drug repurposing strategies of relevance for Parkinson\u2019s disease","volume":"9","author":"Fletcher","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.arr.2025.102693_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.6026\/97320630009089","article-title":"A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs","volume":"9","author":"Fukuoka","year":"2013","journal-title":"Bioinformation"},{"key":"10.1016\/j.arr.2025.102693_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib71","first-page":"413","article-title":"Immunotherapy in Parkinson\u2019s disease: micromanaging alpha-synuclein aggregation","volume":"5","author":"George","year":"2015","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.arr.2025.102693_bib72","doi-asserted-by":"crossref","first-page":"13543","DOI":"10.1523\/JNEUROSCI.4144-09.2009","article-title":"Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson\u2019s disease","volume":"29","author":"Ghosh","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib73","first-page":"83","article-title":"Discovering Cures in Medicine","author":"Gillies","year":"2018","journal-title":"Build. Theor. Heuristics Hypotheses Sci."},{"key":"10.1016\/j.arr.2025.102693_bib74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd1383","article-title":"Inflammatory resolution: new opportunities for drug discovery","volume":"3","author":"Gilroy","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"80","key":"10.1016\/j.arr.2025.102693_bib75","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.286.5439.531","article-title":"Molecular classification of cancer: class discovery and class prediction by gene expression monitoring","volume":"286","author":"Golub","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.arr.2025.102693_bib76","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1582-4934.2008.00402.x","article-title":"Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling","volume":"12","author":"Gorman","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.arr.2025.102693_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1358\/dnp.2009.22.1.1303754","article-title":"The year\u2019s new drugs & biologics-2008","volume":"22","author":"Graul","year":"2009","journal-title":"Drug N. Perspect."},{"key":"10.1016\/j.arr.2025.102693_bib78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)."},{"key":"10.1016\/j.arr.2025.102693_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-015-0331-3","article-title":"Ceruloplasmin activity and iron chelation treatment of patients with Parkinson\u2019s disease","volume":"15","author":"Grolez","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"\u03b22-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib81","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amjopharm.2006.12.001","article-title":"Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson\u2019s disease","volume":"4","author":"Guay","year":"2006","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.arr.2025.102693_bib82","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11030-021-10217-3","article-title":"Artificial intelligence to deep learning: machine intelligence approach for drug discovery","volume":"25","author":"Gupta","year":"2021","journal-title":"Mol. Divers."},{"key":"10.1016\/j.arr.2025.102693_bib83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jns.2012.11.009","article-title":"Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy","volume":"325","author":"Han","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib84","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1476-5381.2009.00486.x","article-title":"Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection","volume":"159","author":"Harkavyi","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.arr.2025.102693_bib86","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/jnc.12751","article-title":"Dyskinesia in Parkinson\u2019s disease: mechanisms and current non-pharmacological interventions","volume":"130","author":"Heumann","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2025.102693_bib87","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2025.102693_bib88","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","article-title":"Amantadine: the journey from fighting flu to treating Parkinson disease","volume":"78","author":"Hubsher","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00177","article-title":"One for all? Hitting multiple Alzheimer\u2019s disease targets with one drug","volume":"10","author":"Hughes","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib90","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1145\/3307339.3342185","article-title":"Multivariate multi-step deep learning time series approach in forecasting Parkinson\u2019s disease future severity progression","author":"Ismail","year":"2019","journal-title":": Proc. 10th Acm Int. Conf. Bioinforma., Comput. Biol. Health Inform."},{"key":"10.1016\/j.arr.2025.102693_bib91","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2017.10.030","article-title":"One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson\u2019s disease in Japan","volume":"383","author":"Iwaki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib92","unstructured":"Jagannatha Rao, K.S., 2007. Studies on alpha-synuclein aggregation and the effect of dietary curcumin derivative: Relevance to Parkinson\u2019s disease."},{"key":"10.1016\/j.arr.2025.102693_bib93","first-page":"497","article-title":"1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned model of parkinson\u2019s disease, with emphasis on mice and nonhuman primates","volume":"54","author":"Jakowec","year":"2004","journal-title":"Comp. Med."},{"key":"10.1016\/j.arr.2025.102693_bib94","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.drudis.2013.11.005","article-title":"Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines","volume":"19","author":"Jin","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2018.05.035","article-title":"Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"147","author":"Johnston","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2025.102693_bib96","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson\u2019s disease: current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.arr.2025.102693_bib97","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1. 3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2025.102693_bib98","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/00003088-200039040-00001","article-title":"Clinical pharmacokinetics of ropinirole","volume":"39","author":"Kaye","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.arr.2025.102693_bib99","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.drudis.2012.05.007","article-title":"Drug discovery in pharmaceutical industry: productivity challenges and trends","volume":"17","author":"Khanna","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.2015.120","article-title":"Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial","volume":"313","author":"Kieburtz","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.arr.2025.102693_bib101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib102","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib103","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.3390\/ijms13078882","article-title":"Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode","volume":"13","author":"Kotb","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib104","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00702-017-1707-x","article-title":"Classification of advanced stages of Parkinson\u2019s disease: translation into stratified treatments","volume":"124","author":"Kr\u00fcger","year":"2017","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2025.102693_bib105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2012.06.050","article-title":"Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms","volume":"1471","author":"Kumar","year":"2012","journal-title":"Brain Res"},{"issue":"80","key":"10.1016\/j.arr.2025.102693_bib106","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.arr.2025.102693_bib107","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib108","first-page":"797","article-title":"Serum uric acid levels and the risk of Parkinson disease","volume":"58","author":"de Lau","year":"2005","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"10.1016\/j.arr.2025.102693_bib109","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mds.27965","article-title":"Pierre D. and the first photographs of Parkinson\u2019s disease","volume":"35","author":"Lewis","year":"2020","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/wnf.0b013e318154c7c4","article-title":"Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease","volume":"30","author":"LeWitt","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib111","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson\u2019s disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.arr.2025.102693_bib113","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"Lonsdale","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.arr.2025.102693_bib114","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2025.102693_bib115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11481-018-09831-0","article-title":"Beta2-adrenoceptor agonists in Parkinson\u2019s disease and other synucleinopathies","volume":"15","author":"Magistrelli","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0099-z","article-title":"Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments","volume":"6","author":"Maiti","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.arr.2025.102693_bib117","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22616","article-title":"Dihydropyridine calcium channel blockers and the progression of parkinsonism","volume":"71","author":"Marras","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib118","first-page":"777","article-title":"Dopamine-modified \u03b1-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2025.102693_bib119","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/3282","article-title":"Drug target validation and identification of secondary drug target effects using DNA microarrays","volume":"4","author":"Marton","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2025.102693_bib120","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/ijms17091585","article-title":"Protein kinases and Parkinson\u2019s disease","volume":"17","author":"Mehdi","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1213\/00000539-198502000-00008","article-title":"Principles of neuroanesthesia for the nonneurosurgical patient with CNS pathophysiology","volume":"64","author":"Messick","year":"1985","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.arr.2025.102693_bib122","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease","volume":"50","author":"Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib123","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"issue":"80","key":"10.1016\/j.arr.2025.102693_bib124","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.arr.2025.102693_bib125","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.410410318","article-title":"Use of desferrioxamine in the treatment of aceruloplasminemia","volume":"41","author":"Miyajima","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jb\/mvr032","article-title":"Drug discovery and development focusing on existing medicines: drug re-profiling strategy","volume":"149","author":"Mizushima","year":"2011","journal-title":"J. Biochem."},{"key":"10.1016\/j.arr.2025.102693_bib127","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.expneurol.2017.05.009","article-title":"Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease","volume":"295","author":"Moreira","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib128","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/brain\/awt224","article-title":"Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson\u2019s disease","volume":"136","author":"Mortiboys","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.arr.2025.102693_bib129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson\u2019s disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.arr.2025.102693_bib131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-8-47","article-title":"Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism","volume":"8","author":"Myhre","year":"2008","journal-title":"BMC Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib132","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate \u03b1-synuclein cytotoxicity in disease-modifying therapy for Parkinson\u2019s disease","volume":"127","author":"Naoi","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.arr.2025.102693_bib133","first-page":"1","article-title":"Therapeutic drug repurposing, repositioning and rescue","volume":"57","author":"Naylor","year":"2015","journal-title":"Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib134","author":"Nyholm","year":"2003","journal-title":"Pharmacother. Park. \u2019S. Dis. -Obs. Innov."},{"key":"10.1016\/j.arr.2025.102693_bib135","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nrd1900","article-title":"Finding new tricks for old drugs: an efficient route for public-sector drug discovery","volume":"4","author":"O\u2019Connor","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib136","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1212\/01.wnl.0000262033.01945.9a","article-title":"Individual dopaminergic neurons show raised iron levels in Parkinson disease","volume":"68","author":"Oakley","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib137","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: A guide for neuroscientists","volume":"139","author":"Oertel","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2025.102693_bib138","first-page":"157","article-title":"Drug repositioning: concept, classification, methodology, and importance in rare\/orphans and neglected diseases","volume":"8","author":"de Oliveira","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib139","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","article-title":"Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial","volume":"77","author":"Pagan","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib140","first-page":"30","article-title":"Parkinson\u2019s disease: recent advances","volume":"60","author":"Pandey","year":"2012","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.arr.2025.102693_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k2701","article-title":"New uses for old drugs","author":"Pantziarka","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.arr.2025.102693_bib142","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nature04788","article-title":"Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin","volume":"441","author":"Park","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.arr.2025.102693_bib143","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/17460441.2013.741580","article-title":"Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1","volume":"8","author":"Parkes","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib144","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/mds.25639","article-title":"safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson\u2019s disease (STEADY-PD)","volume":"28","author":"Parkinson Study Group., Phase I.I","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib145","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib146","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1124\/jpet.300.3.958","article-title":"A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells","volume":"300","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.arr.2025.102693_bib147","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14656561003598919","article-title":"Levodopa in Parkinson\u2019s disease: from the past to the future","volume":"11","author":"Pezzoli","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.arr.2025.102693_bib148","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2025.102693_bib149","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/ng.3570","article-title":"Detection and interpretation of shared genetic influences on 42 human traits","volume":"48","author":"Pickrell","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.arr.2025.102693_bib150","author":"Poewe","year":"2009","journal-title":"Park. Dis., Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.arr.2025.102693_bib151","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","article-title":"The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions","volume":"24","author":"Polamreddy","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib152","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00228-018-2561-y","article-title":"Non-steroidal anti-inflammatory drugs and risk of Parkinson\u2019s disease in the elderly population: a meta-analysis","volume":"75","author":"Poly","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib153","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","article-title":"Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD) A randomized trial","volume":"89","author":"Postuma","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib154","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson\u2019s disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib155","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arr.2025.102693_bib156","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2014.12.101","article-title":"A bidirectional drug repositioning approach for Parkinson\u2019s disease through network-based inference","volume":"457","author":"Rakshit","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.arr.2025.102693_bib157","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","article-title":"Neuroprotective agents for clinical trials in Parkinson\u2019s disease: a systematic assessment","volume":"60","author":"Ravina","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2025.102693_bib158","series-title":"The Evolution Of Drug Discovery: From Traditional Medicines To Modern Drugs","author":"Ravina","year":"2011"},{"key":"10.1016\/j.arr.2025.102693_bib159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ddstr.2011.09.007","article-title":"Drug repurposing through nonhypothesis driven phenotypic screening","volume":"8","author":"Reaume","year":"2011","journal-title":"Drug Discov. Today Ther. Strateg."},{"issue":"5","key":"10.1016\/j.arr.2025.102693_bib160","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The Rise, Fall and Subsequent Triumph of Thalidomide: Lessons Learned in Drug Development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.arr.2025.102693_bib161","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib162","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","article-title":"Association of coffee and caffeine intake with the risk of Parkinson disease","volume":"283","author":"Ross","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.arr.2025.102693_bib163","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mds.27063","article-title":"Projection of the prevalence of Parkinson\u2019s disease in the coming decades: Revisited","volume":"33","author":"Rossi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib164","first-page":"73","article-title":"Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"key":"10.1016\/j.arr.2025.102693_bib165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nature03180","article-title":"\u03b2-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression","volume":"433","author":"Rothstein","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.arr.2025.102693_bib166","first-page":"244","article-title":"Prospects of statins in Parkinson disease","volume":"17","author":"Roy","year":"2011","journal-title":"Neurosci"},{"key":"10.1016\/j.arr.2025.102693_bib167","first-page":"552","article-title":"Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson\u2019s disease","volume":"26","author":"Sandor","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2025.102693_bib168","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s12640-019-00015-z","article-title":"The neuroprotective effect of doxycycline on neurodegenerative diseases","volume":"35","author":"Santa-Cec\u00edlia","year":"2019","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.arr.2025.102693_bib169","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-019-01104-1","article-title":"Targeting \u03b1-synuclein in Parkinson\u2019s disease: progress towards the development of disease-modifying therapeutics","volume":"79","author":"Savitt","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2025.102693_bib170","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-014-0205-z","article-title":"Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson\u2019s disease","volume":"28","author":"Schaeffer","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.arr.2025.102693_bib171","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2004.035980","article-title":"Present and future drug treatment for Parkinson\u2019s disease","volume":"76","author":"Schapira","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.arr.2025.102693_bib172","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","article-title":"Molecular and clinical prodrome of Parkinson disease: implications for treatment","volume":"6","author":"Schapira","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib173","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/med.21627","article-title":"Repurposing approved drugs on the pathway to novel therapies","volume":"40","author":"Schein","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.arr.2025.102693_bib174","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/ijms21134766","article-title":"Caffeine: An overview of its beneficial effects in experimental models and clinical trials of parkinson\u2019s disease","volume":"21","author":"Schepici","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib175","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jama.1972.03210070026008","article-title":"Amantadine in Parkinson\u2019s disease: review of more than two years\u2019 experience","volume":"222","author":"Schwab","year":"1972","journal-title":"Jama"},{"key":"10.1016\/j.arr.2025.102693_bib176","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","article-title":"Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial","volume":"71","author":"Schwarzschild","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib177","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neulet.2017.12.049","article-title":"Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson\u2019s disease","volume":"666","author":"Sekar","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.arr.2025.102693_bib178","article-title":"Repositioning drugs and biologics: Retargeting old\/existing drugs for potential new therapeutic applications","volume":"4","author":"Sekhon","year":"2013","journal-title":"J. Pharm. Educ. Res."},{"key":"10.1016\/j.arr.2025.102693_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2004.02.083","article-title":"Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice","volume":"1037","author":"Selley","year":"2005","journal-title":"Brain Res"},{"key":"10.1016\/j.arr.2025.102693_bib180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib181","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/TCRM.S144481","article-title":"Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson\u2019s disease","author":"Sharma","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.arr.2025.102693_bib182","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1172\/JCI133398","article-title":"Striatal Kir2 K+\u2009channel inhibition mediates the antidyskinetic effects of amantadine","volume":"130","author":"Shen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.arr.2025.102693_bib183","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1\u03b1 contributes to neurodegeneration in Parkinson\u2019s disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.arr.2025.102693_bib184","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2010.07132.x","article-title":"The relevance of iron in the pathogenesis of Parkinson\u2019s disease","volume":"118","author":"Sian-H\u00fclsmann","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.arr.2025.102693_bib185","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2025.102693_bib186","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","article-title":"Depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation","volume":"111","author":"da Silva","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-019-1252-3","article-title":"Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: Protocol for a single-centre, randomized, double-blind, placebo-controlled trial","volume":"19","author":"Silveira","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib188","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mds.20345","article-title":"Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson\u2019s disease","volume":"20","author":"Silverdale","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib189","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1124\/mol.108.049981","article-title":"Expression and 1, 4-dihydropyridine-binding properties of brain L-type calcium channel isoforms","volume":"75","author":"Sinnegger-Brauns","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1099\/0022-1317-38-1-97","article-title":"On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride","volume":"38","author":"Skehel","year":"1978","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.arr.2025.102693_bib191","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1476-5381.2010.01120.x","article-title":"Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal","volume":"164","author":"Sohn","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib192","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0377-1237(17)30452-5","article-title":"Sildenafil-oral medication for erectile dysfunction-a review","volume":"55","author":"Srinath","year":"1999","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.arr.2025.102693_bib193","doi-asserted-by":"crossref","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.arr.2025.102693_bib194","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1517\/14656566.2015.1086748","article-title":"Rasagiline for the treatment of Parkinson\u2019s disease: an update","volume":"16","author":"Stocchi","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.arr.2025.102693_bib195","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00693","article-title":"Emerging treatment approaches for Parkinson\u2019s disease","volume":"12","author":"Stoker","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib196","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.3595","article-title":"Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks","volume":"20","author":"Strittmatter","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2025.102693_bib197","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.arr.2025.102693_bib198","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1021\/acschemneuro.7b00478","article-title":"Mechanism underlying the effectiveness of deferiprone in alleviating Parkinson\u2019s disease symptoms","volume":"9","author":"Sun","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib199","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nn.2372","article-title":"Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss","volume":"12","author":"Tain","year":"2009","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib200","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1353-8020(00)00050-X","article-title":"Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP)","volume":"7","author":"Takanashi","year":"2001","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib201","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuron.2017.03.020","article-title":"The retromer supports AMPA receptor trafficking during LTP","volume":"94","author":"Temkin","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.arr.2025.102693_bib202","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/01.STR.0000255227.96365.37","article-title":"Screening potential therapies: lessons learned from new paradigms used in Parkinson disease","volume":"38","author":"Tilley","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.arr.2025.102693_bib203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug N. Perspect."},{"key":"10.1016\/j.arr.2025.102693_bib204","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fnmol.2018.00165","article-title":"Simvastatin inhibits activation of NADPH oxidase\/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models","volume":"11","author":"Tong","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.arr.2025.102693_bib205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-015-1485-1","article-title":"Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies","volume":"131","author":"Uchihara","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.arr.2025.102693_bib206","first-page":"3974","article-title":"In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson\u2019s disease","volume":"27","author":"Uenaka","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.arr.2025.102693_bib207","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138920309789351921","article-title":"Biophysics of Parkinson\u2019s disease: structure and aggregation of \u03b1-synuclein","volume":"10","author":"Uversky","year":"2009","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.arr.2025.102693_bib208","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ana.20256","article-title":"PINK1 mutations are associated with sporadic early-onset parkinsonism","volume":"56","author":"Valente","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib209","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1753193418805249","article-title":"The teratogenic effects of thalidomide on limbs","volume":"44","author":"Vargesson","year":"2019","journal-title":"J. Hand Surg. (Eur."},{"key":"10.1016\/j.arr.2025.102693_bib210","doi-asserted-by":"crossref","first-page":"42655","DOI":"10.1074\/jbc.M505910200","article-title":"Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of \u03b1-synuclein, parkin, and DJ-1 in Caenorhabditis elegans","volume":"280","author":"Ved","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2025.102693_bib211","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/17512433.2014.966812","article-title":"New treatments for the motor symptoms of Parkinson\u2019s disease","volume":"7","author":"Vijverman","year":"2014","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.arr.2025.102693_bib212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-9158-1-14","article-title":"Current advances in using neurotrophic factors to treat neurodegenerative disorders","author":"Weissmiller","year":"2012","journal-title":"Transl. Neurodegener., 1, 14. Available Pmc"},{"key":"10.1016\/j.arr.2025.102693_bib213","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","article-title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease","volume":"298","author":"West","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib214","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib215","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/mds.23687","article-title":"A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson\u2019s disease","volume":"26","author":"Wong","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.arr.2025.102693_bib216","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/practneurol-2012-000463","article-title":"When the going gets tough: how to select patients with Parkinson\u2019s disease for advanced therapies","volume":"13","author":"Worth","year":"2013","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.arr.2025.102693_bib217","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/brain\/aws360","article-title":"The cerebellum in Parkinson\u2019s disease","volume":"136","author":"Wu","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.arr.2025.102693_bib218","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbi.2018.01.004","article-title":"Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the \u03b12-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson\u2019s disease","volume":"69","author":"Yssel","year":"2018","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.arr.2025.102693_bib219","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.arr.2025.102693_bib220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1093-3263(01)00126-7","article-title":"COMPARE: a web accessible tool for investigating mechanisms of cell growth inhibition","volume":"20","author":"Zaharevitz","year":"2002","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.arr.2025.102693_bib221","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/ncomms4828","article-title":"Mutation in VPS35 associated with Parkinson\u2019s disease impairs WASH complex association and inhibits autophagy","volume":"5","author":"Zavodszky","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.arr.2025.102693_bib222","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/13543784.8.5.697","article-title":"Ropinirole in the treatment of Parkinson\u2019s disease","volume":"8","author":"Zesiewicz","year":"1999","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.arr.2025.102693_bib223","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12640-009-9140-z","article-title":"Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson\u2019s disease","volume":"19","author":"Zhang","year":"2011","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.arr.2025.102693_bib224","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1196\/annals.1427.023","article-title":"Oxidative stress in Parkinson\u2019s disease: a mechanism of pathogenic and therapeutic significance","volume":"1147","author":"Zhou","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372500039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156816372500039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:11:58Z","timestamp":1750209118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156816372500039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":224,"alternative-id":["S156816372500039X"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2025.102693","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does drug repurposing bridge the gaps in management of Parkinson\u2019s disease? Unravelling the facts and fallacies","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2025.102693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102693"}}